Home » Adventrx Partners With Veterans Affairs
Adventrx Partners With Veterans Affairs
Adventrx Pharmaceuticals has signed a cooperative R&D agreement with the Department of Veterans Affairs (VA) that permits VA clinical sites to participate in a Phase III trial of ANX-510 for the treatment of metastatic colorectal cancer.
To be conducted at up to 100 sites across the U.S. and in other countries, the randomized trial will test progression-free survival in 1,200 subjects. Patients will be given ANX-510 (CoFactor) or leucovorin, each in combination with bevacizumab (Avastin) and 5-fluorouracil (5-FU).
CoFactor is designed to replace leucovorin as the preferred method of reducing associated toxicity of 5-FU, a cancer chemotherapy agent, according to Adventrx.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May